TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Specificity of hematuria dipstick test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost savings using the model
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in measures of agitation and aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events resulting in dropout
Endpoint domain: Adverse events/effects
Primary endpoint: Trial quality improvement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: first nonfatal event
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of access establishment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average procedural time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Satisfaction with pain relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction in contact pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in peak pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in contact area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total cost of LF‐LAM per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accuracy in firearm use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time in firearm scenarios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Judgement in firearm scenarios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with pharmacist
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breathing-related ED or hospital visits
Endpoint domain: Adverse events/effects
Primary endpoint: 4-year primary graft patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: diabetes empowerment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subendometrial vascularisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pulsatility Index (PI) in spiral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of acute cardiac complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in TUG test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee extension strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Balance confidence improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hydrolysis rates of plant stanyl and steryl fatty acid esters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in PTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: risk of fatal CHD
Endpoint domain: Mortality/survival
Primary endpoint: total number of liver-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median hospital cost for a 30-day period
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction of pro-inflammatory cytokines (IFN-gamma and TNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Enhancement of anti-inflammatory cytokine (IL-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean compliance percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of smoker participation in community-wide stop-smoking contests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in BMI Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection rate at day 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality ratings of homework completion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to total oral feedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to find answers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of serum HA and LN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of fibrous tissue proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental plasma cholecystokinin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incremental amylase output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incremental integrated gallbladder contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recurrence of arrhythmia
Endpoint domain: Mortality/survival
Primary endpoint: Agreement with secure storage importance during emotional or stressful times
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skin-care PU prevention behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PASI-50 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Exercise tolerance improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall provider visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Psychiatrist visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: duration of pain-free period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for radiofrequency ablation (RFA)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to radiofrequency ablation (RFA)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sentinel lymph nodes (SLNs) identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Duration of hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dyspnea resolution time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Infiltration absorption rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: albuterol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rescue medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ecchymosis
Endpoint domain: Adverse events/effects
Primary endpoint: Influenza-like illness (ILI) rates
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory-confirmed virus rates
Endpoint domain: Adverse events/effects
Primary endpoint: levels of serumal ECP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean trough motavizumab concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient injection site erythema
Endpoint domain: Adverse events/effects
Primary endpoint: Antimotavizumab reactivity
Endpoint domain: Adverse events/effects
Primary endpoint: stool fluid excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: electrolyte loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: emotional and behavioural problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fever or infection
Endpoint domain: Adverse events/effects
Primary endpoint: β‐cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual LN metastases after CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Pathological complete remission (ypT0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local failure rate after local excision
Endpoint domain: Adverse events/effects
Primary endpoint: Driver's decision to pass or stop at yellow lights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time headway of participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter placement failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Interleukin-8 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: safety and efficacy of SOCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: handwriting speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of delusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEF variance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: symptomatic scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: No pathologic findings at UV-B or sun-exposed sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Successful response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of contact with the healthcare system
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Odds of undergoing an HIV test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Likelihood of DAD (three or more drinks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of drinks consumed before driving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imputed improvements in at-work productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Risk of conversion to glaucoma
Endpoint domain: Mortality/survival
Primary endpoint: Exiting the study due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality risk in older adults with severe depression
Endpoint domain: Mortality/survival
Primary endpoint: Mean utility values for life with severe anemia and splenomegaly and life with chronic bone pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: β-cell function (disposition index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: total GSIS (iAUC of C‐peptide0‐240 /Glc0‐240)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Agreement between apnea hypopnea index on PSG and AHI on home PM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical failure rates for home vs. in-laboratory PM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant preference for home over in-laboratory testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychomotor vigilance task (PVT) lapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified maintenance of wakefulness (MWT) sleep latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVT speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADSES scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean femoral component rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically meaningful symptom improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: blastocyst development rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blastocyst utilization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD62p levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angina episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Hausdorff distance between boundaries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of the geometric distortion compensation algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDA levels after aortic declamping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of pregnancies ascribed to method failure
Endpoint domain: Mortality/survival
Primary endpoint: Irregular bleeding (break‐through bleeding or spotting)
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation of the study due to side effects
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: subsequent fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year liver-related death
Endpoint domain: Mortality/survival
Primary endpoint: 5-year liver decompensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year HCC occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development of TB
Endpoint domain: Adverse events/effects
Primary endpoint: recurrence of syncope or presyncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antidepressant-specific side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Voice Handicap Index (VHI-10) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived Stress Scale (PSS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 6 min hall walk (6 MHW) distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barnes akathisia scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simpson Angus EPS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from allograft rejection requiring treatment at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving beta-blockers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving mineralocorticoid receptor antagonists
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doses of beta-blockers received (≥100% of target)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to try snus
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to pay for product
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow-mediated dilatation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FFA levels increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: aggregate incidence of predefined moderate or severe complications
Endpoint domain: Adverse events/effects
Primary endpoint: Thyroid uptake on TcGS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Blood flow in ischaemic retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mental health of carers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Polysomnogram arousals and apnea indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in area of hyperemia (AH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased use of cross‐cultural communication PACT questions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penalty time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Health behavior compliance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hospital anxiety
Endpoint domain: Adverse events/effects
Primary endpoint: reduction of symptom burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year freedom from biochemical failure rate
Endpoint domain: Mortality/survival
Primary endpoint: Pap-test rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current use of family planning methods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in POEM scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high-density lipoprotein parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinically significant device‐pocket hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Lymphocytic infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FMA (Functional Movement Assessment) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WMFT (Wolf Motor Function Test) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' levels of engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mortality due to cancer progression
Endpoint domain: Mortality/survival
Primary endpoint: 24-hour blood pressure monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thrombosis extent in dialyser
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: duration of rehabilitation after hip fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean level of sensory anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of sensory analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial Wrinkle Scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of stressors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: urinary irritation and restlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forearm PS exposition after ischaemic exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Young Mania Rating Scale (YMRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions (CGI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BIS measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to stimulant-like effects of ethanol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation response after alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol response after alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: maximum decrease in diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients eligible for chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cytokine concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Saccharin clearance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Parent-rated ADHD symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean failure load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tinnitus distress reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response to duloxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RA-diagnosis sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DMARD-start sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value for RA-diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes